1350P Phase I/II trial shows promising efficacy of nadunolimab in combination with platinum doublet as second-line therapy in patients with NSCLC
| Autor: | Paulus, A., Zemaitis, M., Cicenas, S., Zvirbule, Z., Rydberg-Millrud, C., Magnusson, S., Losic, N., Tersago, D., Paz-Ares, L.G. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S853-S853 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|